The new Category I medicine developed by CGeneTech (Suzhou, China) Co Ltd for treatment of Type 2 diabetes has received approval for clinic trial, according to a recent announcement by SIP BioBAY.

Diabetes is currently a major threat to human health. According to International Diabetes Federation (IDF), there are more than 100 million diabetes patients in China.

The new medicine (CGT-8012) was developed based on new target points identified through 10-year clinic verification. It is safe, effective and does not cause fasting hypoglycemia or weight gain. Moreover, it is given orally. Therefore, it has caught great attention of the pharmaceutical industry in recent years.